Trial Profile
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Pulmotect
- 01 Dec 2021 Results published in the Media Release
- 24 Sep 2021 Primary endpoint has been met. (Severity of COVID-19) as per Pulmotect media release
- 24 Sep 2021 Results published in the Pulmotect Media Release